Compounds and methods for inhibiting NHE-mediated reverse transport in the treatment of fluid retention or salt overload related diseases and gastrointestinal diseases
The disclosure relates to diseases associated with fluid retention or salt overload, such as heart failure (especially congestive heart failure), chronic kidney disease, end-stage renal disease, liver disease, and peroxisome proliferator activated receptor (PPAR) gamma agonist-induced It relates to compounds and methods for the treatment of fluid retention. The present disclosure further relates to compounds and methods for the treatment of hypertension. The present disclosure further relates to compounds and methods for the treatment of gastrointestinal diseases, including the treatment and alleviation of pain associated with gastrointestinal diseases.本開示は、体液貯留又は塩過負荷に関係する疾患、例えば心不全（特に鬱血性心不全）、慢性腎疾患、末期腎疾患、肝疾患、及びペルオキシソーム増殖剤活性化受容体（ＰＰＡＲ）ガンマアゴニスト誘発の体液貯留の治療のための化合物並びに方法に関する。本開示は、更に、高血圧の治療のための化合物及び方法に関する。本開示は、更に、消化管疾患に関係する疼痛の治療及び軽減を含む、消化管疾患の治療のための化合物及び方法に関する。
